1
|
Morteza-Semnani K, Saeedi M, Akbari J, Hedayati S, Hashemi SMH, Rahimnia SM, Babaei A, Ghazanfari M, Haghani I, Hedayati MT. Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method. J Biomater Sci Polym Ed 2022; 33:2325-2352. [PMID: 35848460 DOI: 10.1080/09205063.2022.2103626] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Terbinafine (TER) is a promising candidate medication for the topical treatment of fungal infections. However, its solubility in water and skin permeability are limited. To overcome these limitations, a Terbinafine niosome and niosomal gel was developed. The impact of cholesterol:surfactants on terbinafine incorporated niosome (terbinasome) preparations was examined. Differential scanning calorimetry (DSC), photon correlation spectroscopy (PCS), scanning electron microscopy (SEM), and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy were used to assess the morphological features of terbinasome and the physicochemical characteristics of TER in terbinasome. The obtained results has shown that Chol enhanced the diameter of the terbinasome from 123.20 ± 2.86 to 701.93 ± 17.72 nm. The highest encapsulation of terbinafine was estimated to be around 66% due to the cholesterol:surfactants ratio in the terbinasome was 1:3 and 1:6. Additional examination has revealed that changes in the cholesterol:surfactants ratio can result in a change in the PDI value of between 0.421 ± 0.004 and 0.712 ± 0.011. The terbinasome gel was prepared and tested for pharmaceutical testing, including pH, viscosity, spreadability, and stability. The percentage of TER dissolution from terbinasome were determined more than 80% and showed quickest drug release. In a cutaneous permeability examination, the quantity of TER in the cutaneous layers and the receiver compartment were higher for the terbinasome gel than for the TER simple gel. The terbinasome's cell viability was around 90% (HFF cell line) and MTT experiment demonstrated that the terbinasome was not cytotoxic. The MIC of the terbinasome was lower than pure drug against Aspergillus, Fusarium, and Trichophyton. The terbinasomal gels were non-irritant (score < 2) in the cutaneous irritation examination performed on Wistar rats. The research suggests that the optimized terbinasome may be used as a nano-vesicle for TER drug administration, hence opening up new possibilities for the treatment of cutaneous infections.
Collapse
Affiliation(s)
- Katayoun Morteza-Semnani
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Majid Saeedi
- Pharmaceutical Sciences Research Centre, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.,Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Jafar Akbari
- Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Shakiba Hedayati
- Student Research Committee Center, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyyed Mohammad Hassan Hashemi
- Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee Center, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyyed Mobin Rahimnia
- Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee Center, Mazandaran University of Medical Sciences, Sari, Iran
| | - Amirhossein Babaei
- Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee Center, Mazandaran University of Medical Sciences, Sari, Iran
| | - Mona Ghazanfari
- Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.,Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
| | - Iman Haghani
- Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
| | - Mohammad Taghi Hedayati
- Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.,Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
2
|
Abstract
BACKGROUND In this study, fluvastatin (FVT) nanosuspensions containing cyclodextrin were developed to improve oral bioavailability. METHODS FVT nanosuspensions containing cyclodextrin were prepared by a high pressure homogenization technique. The nanosuspensions system was then characterized by transmission electron microscopy (TEM), particle size, differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD). In addition, in vitro drug release properties, pharmacokinetics and pharmacodynamics were also investigated in detail. RESULTS After lyophilization, the nanosuspensions could be redispersed gently and with a narrow particle size distribution, but the particle size has no obvious change. The powder X-ray diffraction and differential scanning calorimetry of FVT nanosuspensions showed that FVT existed in amorphous form in nanosuspensions. In vitro release, FVT nanosuspensions have sustained-release properties. Meanwhile, FVT nanosuspensions could significantly modify the pharmacokinetic profile and increase the bioavailability of FVT by more than 2.4-fold in comparison with the FVT capsules group. In vivo irritation test showed that there was almost no evidence of hemorrhagic mucosal erosion and intestinal villus destruction in rat gastric mucosa. CONCLUSION The combination of nanocrystallization and cyclodextrin complexation techniques is a new attempt to formulate poorly water-soluble FVT.
Collapse
Affiliation(s)
- Jun Li
- School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China,
- Department of Intensive Care Unit, Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China
| | - Min Yang
- Department of Intensive Care Unit, Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China
| | - Wen-Rong Xu
- School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China,
| |
Collapse
|
3
|
Nomura Y, Lee M, Fukui C, Watanabe K, Olsen D, Turley A, Morishita Y, Kawakami T, Yuba T, Fujimaki H, Inoue K, Yoshida M, Ogawa K, Haishima Y. Proof of concept testing of a positive reference material for in vivo and in vitro skin irritation testing. J Biomed Mater Res B Appl Biomater 2017; 106:2807-2814. [PMID: 29226582 DOI: 10.1002/jbm.b.34061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 11/01/2017] [Accepted: 11/26/2017] [Indexed: 11/06/2022]
Abstract
In vivo and in vitro irritation testing is important for evaluating the biological safety of medical devices. Here, the performance of positive reference materials for skin irritation testing was evaluated. Four reference standards, referred to as Y-series materials, were analyzed: a polyvinyl chloride (PVC) sheet spiked with 0 (Y-1), 1.0 (Y-2), 1.5 (Y-3), or 10 (Y-4) parts of Genapol X-080 per 100 parts of PVC by weight. Y-1, Y-2, and Y-3 did not induce skin irritation responses in an in vitro reconstructed human epidermis (RhE) tissue model, as measured by tissue viability or interleukin-1α release, or in an in vivo intracutaneous response test using rabbits. In contrast, Y-4 extracts prepared with saline or sesame oil at 37°C and 50°C clearly elicited positive irritation responses, including reduced viability (< 50%) and significantly higher interleukin-1α release compared with the solvent alone group, in the RhE tissue model and an intracutaneous response test, where substantial necrosis was observed by histopathology. The positive skin irritation responses induced in vitro under various extraction conditions, as well as those elicited in vivo, indicate that Y-4 is an effective extractable positive control material for in vivo and in vitro skin irritation tests of medical devices. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2807-2814, 2018.
Collapse
Affiliation(s)
- Yusuke Nomura
- Division of Medical Devices, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Michelle Lee
- Business Unit of Sterigenics International, Nelson Laboratories, Inc., Salt Lake City, Utah, 84123
| | - Chie Fukui
- Division of Medical Devices, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Kayo Watanabe
- Research Department, Public Welfare Institute of Scientific Research Foundation, Koganei, Tokyo, 184-0015, Japan
| | - Daniel Olsen
- Business Unit of Sterigenics International, Nelson Laboratories, Inc., Salt Lake City, Utah, 84123
| | - Audrey Turley
- Business Unit of Sterigenics International, Nelson Laboratories, Inc., Salt Lake City, Utah, 84123
| | - Yuki Morishita
- Division of Medical Devices, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Tsuyoshi Kawakami
- Division of Environmental Chemistry, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Toshiyasu Yuba
- Kawasumi Laboratories, INC., Corporate Research and Development Division, Konan, Minato-ku, Tokyo, 108-6109, Japan
| | - Hideo Fujimaki
- Research Department, Public Welfare Institute of Scientific Research Foundation, Koganei, Tokyo, 184-0015, Japan
| | - Kaoru Inoue
- Division of Pathology, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Midori Yoshida
- Division of Pathology, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Kumiko Ogawa
- Division of Pathology, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| | - Yuji Haishima
- Division of Medical Devices, National Institute of Health Sciences, Setagaya-ku, Tokyo, 158-8501, Japan
| |
Collapse
|